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Not all intravenous immunoglobulin preparations are equally
well tolerated
Abstract
Intravenous immunoglobulin (IVIG) is used for many indications beyond the original substitution in
primary antibody deficiency. Whereas many reports mention adverse reactions, no comparative data
exist concerning the incidence of side-effects among the different brands of IVIG. We describe here our
experience with the use of different IVIG formulations and their tolerability in a select cohort of 40
patients. The IVIG dose ranged from 0.4 to 3 g/kg/day and was given for 1-2742 days. Fourteen patients
(35%) experienced mild to severe adverse reactions during or within 48 h of administration of standard
IVIG preparation, which did not recur after switching to an alternative preparation. Adverse reactions
included headache, fever, chills, nausea, emesis, hypotension and muscle cramps. One patient
experienced a severe adverse reaction; he had a 3-day headache following IVIG infusion. Among the 16
patients who received alternative preparation initially, none experienced adverse reactions. In
conclusion, this study shows that IVIG preparations are not all equally well tolerated in patients. The
data suggest that, perhaps to a comparable extent to the preparation itself, the infusion rate has a major
effect. If a reduction in the infusion rate does not minimize side-effects, one should consider switching
the IVIG formulation.
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Intravenous immunoglobulin (IVIG) is used for many 
indications beyond the original substitution in primary 
antibody deficiency. Whereas many reports mention ad-
verse reactions, no comparative data exist concerning 
the incidence of side-effects among the different brands 
of IVIG. We describe here our experience with the use of 
different IVIG formulations and their tolerability in a se-
lect cohort of 40 patients. The IVIG dose ranged from 0.4 
to 3 g/kg/day and was given for 1–2742 days. Fourteen 
patients (35%) experienced mild to severe adverse reac-
tions during or within 48 h of administration of standard 
IVIG preparation, which did not recur after switching to 
an alternative preparation. Adverse reactions included 
headache, fever, chills, nausea, emesis, hypotension and 
muscle cramps. One patient experienced a severe ad-
verse reaction; he had a 3-day headache following IVIG 
infusion. Among the 16 patients who received alternative 
preparation initially, none experienced adverse reac-
tions. In conclusion, this study shows that IVIG prepa-
rations are not all equally well tolerated in patients. The 
data suggest that, perhaps to a comparable extent to the 
preparation itself, the infusion rate has a major effect. If 
a reduction in the infusion rate does not minimize side-
effects, one should consider switching the IVIG formu-
lation. Key words: intravenous immunoglobulin; adverse 
drug reaction; prevention; toxic epidermal necrolysis; 
hypo gammaglobulinaemia; lung transplantation.
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The range of diseases for which intravenous immunoglo-
bulin (IVIG) is used has increased rapidly since its initial 
use in primary antibody deficiency (1, 2). Important rea-
sons for this expansion in IVIG use are its effectiveness 
and safety. However, side-effects and adverse reactions 
do occur. Most adverse effects are mild and transient, 
including headaches, flushes, fever, chills, fatigue, nau-
sea, diarrhoea, blood pressure changes and tachycardia. 
Although rare, serious and potentially fatal side-effects 
include anaphylactic reactions, aseptic meningitis, acute 
renal failure and thrombo-embolic complications, such 
as stroke and myocardial infarction (3).
Whereas many reports concentrate on adverse reac-
tions following IVIG infusions (3–8), few studies have 
addressed the potential difference between the different 
IVIG preparations (2, 9, 10) and no comparative data 
exist concerning the incidence of side-effects among the 
different brands of IVIG. During our clinical practice, 
we have observed various IVIG formulations to be of 
different tolerability in our patients. The authors believe 
this is important clinical information for the practical 
use of IVIG, and we therefore report here our experience 
within an 8-year time-period. 
MATERIALS AND METHODS
This retrospective observational study included paediatric and 
adult patients attending our dermatology department for the 
application of IVIG for various clinical indications between 
May 2001 and December 2008.
Patients characteristics and IVIG therapies
Forty patients (25 males, 15 females) were included in the 
study with a median age of 47 years (age range 15–73 ye-
ars). Patient demographic data are displayed in Table SI 
(available from http://adv.medicaljournals.se/article/abst-
ract/10.2340.00015555-3253/Tab1). The indications for IVIG 
included hypogammaglobulinaemia, cytomegalovirus (CMV) 
or Epstein Barr virus (EBV) mismatch in lung transplant re-
cipients (25 cases), substitution for immunoglobulin G (IgG) 
deficiency (1 case), pemphigus vulgaris (1 case), dermatomyo-
sitis (2 cases), atopic dermatitis (1 case) and toxic epidermal 
necrolysis (TEN) (10 cases). EBV mismatch means different 
donor and recipient serological status for EBV, predisposing 
EBV-negative recipients of an EBV-positive graft to EBV 
infection and potentially post-transplant lymphoproliferative 
disease. Two IVIG preparations were predominantly used: 
Redimune NF Liquid® (CSL Behring AG, Bern, Switzerland) 
and Octagam® (Octapharma, Lachen, Switzerland). Two patients 
received Endobulin® (Baxter AG, Volketswil, Switzerland) after 
adverse reactions to Redimune®. The choice of primary IVIG 
preparation was a result of hospital management decision-
making based primarily on availability and price, not on medical 
considerations. The total administration periods were 1952 
patient-days for Redimune®, 20,759 patient-days for Octagam® 
and 7 patient-days for Endobulin® (see Table SI for exact dosa-
ges). Administration periods were calculated as the cumulative 
days on IVIG of all patients; for one patient the total duration 
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of treatment was counted from the first to the last IVIG dose 
(including the days between 2 doses). The patients were not 
specifically instructed to drink before the infusions of all three 
products. Only the patients who had previous adverse events 
received NaCl infusion before IVIG, the other only had NaCl 
to keep the infusion open (500 ml/24 h). A screening process 
(anti-IgA antibodies) before IVIG administration was performed 
in chronic situations, but not for acute situations (TEN). IgA-
deficient patients may form macromolecular complexes with 
anti-IgA antibodies of the recipient of IVIG that can lead to 
anaphylactic reaction. Anaphylaxis can be prevented by using 
IgA-depleted IVIG, even if it is still contaminated with a small 
amount of IgA. In our institution pre-medication is not given 
systematically before starting IVIG.
Classification of reaction
Reactions occurring during or within 48 h of IVIG infusion 
were classified as mild, moderate or severe, based on the clas-
sification of adverse reactions following IVIG proposed by 
Brennan et al. (11), and were defined as follows: 
Mild reactions include headache, fever, chills, nausea, eme-• 
sis, hypotension and muscle cramps. These subside once the 
infusion rate is decreased. 
Moderate reactions include mild reactions worsening, neces-• 
sitating discontinuation of the infusion. 
Severe reactions include moderate reactions persisting or • 
becoming worse or other symptoms, such as tightness of the 
throat, severe shaking, severe breathlessness or wheezing, 
severe dizziness or fainting, sensation of chest tightness or 
collapse. A severe reaction would require the administration 
of adrenaline and further medical attention. Serious and 
potentially fatal side-effects also include, for example, ana-
phylactic reactions, aseptic meningitis, acute renal failure and 
thrombo-embolic complications, such as stroke and myocar-
dial infarction (3).
Statistical methods
The proportion of adverse events was computed separately 
for each preparation of IVIG. For patients who had only one 
IVIG preparation, the rate of adverse events was compared 
using Fisher’s exact test. For patients taking both Redimune® 
and Octagam®, the rate of adverse events was compared using 
McNemar’s test. Analysis was performed using the R program-
ming language (12).
Assuming that adverse events occur in 15% of patients treat-
ed with Redimune® as null hypothesis, our sample size of 28 
patients who had been exposed to Redimune® has a power of 
80% to detect the observed rate of 35% of patients experiencing 
any adverse event.
RESULTS
Thirteen patients (33%) experienced mild and moderate 
adverse reactions during or within 48 h of the admi-
nistration of standard IVIG preparation (Redimune®), 
which did not recur after switching to an alternative 
preparation (Octagam® or Endobulin®). Of patients ta-
king only one preparation (12 taking only Redimune®, 
and 12 taking Octagam®), four experienced adverse 
events, all with Redimune (p = 0.09, Fisher’s exact test). 
For patients taking both Redimune® and Octagam® 
(n = 12), 10 experienced adverse events while on Octa-
gam®, compared with no adverse events on Redimune® 
(p = 0.004, McNemar’s test). Adverse reactions inclu-
ded headache (8 cases), fever (5 cases), chills (3 cases), 
nausea (3 cases), emesis (3 cases), hypotension (1 case) 
and muscle cramps (1 case). In four cases, the presence 
of predisposing conditions was identified: one patient 
experiencing severe headache had a history of migraine 
(No. 9); one patient with nausea and emesis also had 
a symptomatic hypercalcaemia with 133 mmol/l (No. 
12); in two cases the presence of a concomitant infec-
tion was identified (status after treated gastroenteritis 
by patient No. 7, and suspicion of sepsis by patient with 
TEN (No. 25)). Except for two cases, adverse events 
occurred during the first or second infusion of a given 
preparation. One patient (No. 9) experienced severe 
adverse reaction. Among the 16 patients who received 
Octagam® initially, none experienced adverse reactions 
(see Table II in this article and Table SI). 
The management of adverse reactions involved initial 
slowing of the infusion rate (of 50%) or stopping and 
restarting at a slower rate after symptoms had disappea-
red. The standard infusion rate for Redimune® was 0.5 
ml/kg/h for the first 30 min, 0.75 ml/kg/h for a further 
30 min, then 1 ml/kg/h for the rest of the infusion. Oc-
tagam was infused at 30 ml/h for the first 30 min, with 
an increase of 30 ml/h every 30 min until the end of 
the infusion, irrespective of body weight. Endobulin® 
was given at 0.5 ml/kg/h for the first 30 min, with an 
increase of 30 ml/h every 30 min until the end of the 
infusion. In addition, non-steroidal anti-inflammatory 
drugs (NSAIDs) were administered. In case of persisting 
symptoms, a switch to an alternative IVIG formulation 
was undertaken. The second product (Octagam® or En-
dobulin®, see Table II and Table SI)) was well tolerated 
in all cases. The immediate adverse reactions occurring 
during the infusion generally resolved upon slowing 
the infusion rate, except for 3 cases out of 14, where 
the infusion had to be stopped before the planned dose 
(Table SI), patient Nos. 5, 9 and 15). One patient (No. 9) 
experienced a 3-day headache following IVIG infusion, 
requiring hospital stay (in fact the only case in our series 
classified as a severe adverse reaction). The Redimune® 
infusion was stopped and the headache was treated 
symptomatically (with hydration and NSAIDs).
As all adverse reactions were observed on Redi-
mune®, starting with patient No. 29, IVIG was initiated 
with Octagam® as first-line preparation (Table SI, Nos. 
29–40). Patients No. 11 and 12, initiated on Redimune®, 
were subsequently switched to Octagam®. Furthermore, 
Table II. Numbers of patients and adverse events
IVIG preparation Patients treated, n Adverse events, n (%)
Redimune NF Liquid® 28 14 (100)
Octagam® 26 0 (0)
Endobulin® 2 0 (0)
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patient Nos. 1–10, initiated on Octagam®, which had 
been switched to Redimune® for lower drug costs, were 
put back on Octagam® to avoid further reactions. Seven 
of patient Nos. 1–10 had tolerated many infusions of 
Octagam® uneventfully, while experiencing adverse 
reactions when given Redimune® once. Only patient 
Nos 13 and 14, initially treated with Octagam®, who had 
been changed to Redimune®, continued to receive this 
preparation without adverse reactions. No dose-effect 
relationship was observed between IVIG dose and the 
severity of adverse events.
DISCUSSION
IVIG products differ regarding their constituents 
(preservatives and inhibitors of IgG aggregation) and 
physical/chemical characteristics (e.g. lyophilized pow-
der or liquid and pH). According to the World Health 
Organization (WHO), preparations must contain at least 
90% intact IgG with a normal IgG subclass distribution, 
as little IgA as possible, and no Ig fragments or aggre-
gates. IgA-deficient patients may form macromolecular 
complexes with anti-IgA antibodies of the recipient of 
IVIG, which can lead to anaphylactic reaction. Ana-
phylaxis can be prevented by using IgA-depleted IVIG, 
even if it is still contaminated with a small amount of 
IgA (8). Measures taken by manufacturers to ensure 
the safety of the product include careful selection of 
donors, screening for infectious agents and the use of 
modern viral inactivation procedures (2, 13). IVIG pro-
ducts have a final concentration of 3–12% and contain 
1% or less of the total IgG in small aggregates. 
Although in vitro experiments (14) show no dif-
ference in the efficacy of different IVIG brands, no 
comparative data exist concerning the incidence of 
side-effects among the different brands of IVIG. Salt 
and sugar content, osmolality, total volume infused, 
rate of infusion, concentration, and total dose of IVIG 
infused, appear to be associated to some extent with the 
likelihood of side-effects (15). There are currently no 
tests or markers available to predict adverse reactions 
in a given patient and guide the choice of a particular 
IVIG product.
In a study including more than 200 patients receiving 
IVIG for different autoimmune diseases and nearly 
10,000 infusions for relapsing-remitting multiple scle-
rosis patients, the occurrence of adverse effects was 
24–36% after high-dose IVIG, most of which were 
headaches, while all were considered mild adverse 
events (3). In a prospective study of adverse reactions 
in 459 primary antibody-deficient patients receiving 
IVIG, mild or moderate adverse reactions occurred in 
59 (12.9%) patients. The low rate of adverse events in 
comparison with our study (35%) and the one of Katz 
et al. (24–36%) are probably due to their selective 
inclusion criteria: only those having uneventfully re-
ceived at least six infusions were included in the study 
by Brennan et al. (11).
Our experience shows that, in a selected patient 
cohort requiring IVIG substitution mostly for hypo-
gammaglobulinaemia or CMV/EBV mismatches in 
lung transplant recipients and treatment of TEN, Re-
dimune® proved more likely to induce adverse events 
than either Octagam® or Endobulin®. This phenomenon 
was observed repeatedly, even though manufacturer’s 
instructions were followed exactly, including warming 
of the Redimune® to body temperature before infusion, 
except in one case. Adverse events were observed in 
such a consistent fashion that, despite higher drug 
costs, Octagam® was designated as first choice in lung 
transplant recipients. 
Retrospectively, and considering that Redimune® was 
given at the maximal recommended rate, whereas Octa-
gam® and Endobulin® were given at a lower rate than the 
maximum recommended, we consider the infusion rate 
to be a fundamental parameter in the administration of 
IVIG. The limitations of our study include the hetero-
geneous conditions treated, requiring different doses (as 
listed in Table SI). The general state of health of patients 
was heterogeneous, including lung transplant patients 
undergoing extracorporeal photopheresis for different 
indications (bronchiolitis obliterans syndrome, recur-
rent acute allograft rejection), as described previously 
elsewhere (16), intensive-care unit patients in the case 
of TEN, and patients with severe atopic dermatitis. Even 
if the high fever developed by a patient with TEN could 
easily be infection-associated rather than related to the 
IVIG infusion, the symptoms correlated chronologically 
at least in three of the four cases concerned. In one 
case the patient received a non-warmed Redimune® 
IVIG preparation. The main problem is that compari-
son between the different infusion rates is difficult, as 
different administration regimens were used, and the 
concentration of the products differed significantly. 
The administered doses correspond to the recommen-
dations of the manufacturer; however, the maximal 
administration rate differed significantly between the 
three preparations. The standard infusion rate used in 
the patients in this sample and the maximum recom-
mended infusion rate were the same for Redimune® 
(Table III). In comparison, the maximum infusion rate 
recommended for Octagam® is four-fold the standard 
infusion rate given and the maximum recommended 
infusion rate of Endobulin® is eight-fold the standard 
infusion rate (Table III). Accordingly, the concentrations 
of the products differ significantly. The patients were 
not specifically instructed to drink before the infusions 
of all three products. This may be of importance, as it 
is known that hydration of the patient is of outstanding 
importance and may explain why symptoms occurred 
with Redimune®, even though the recommended infu-
sion rate was not exceeded.
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Although our patients had a wide range of conditions, 
they were all seen within our dermatology department 
or in the intensive care unit, which may represent a 
selection bias. The indication for IVIG therapy itself 
may influence the type of adverse reactions: patients 
with neurological disorders are thought to present more 
cutaneous eczematous rashes following IVIG infusion 
(13), but our report does not include such indications 
for IVIG use. 
As this is a retrospective case series, the adverse 
events were not recorded systematically. Whereas TEN 
patients are hospitalized for many days, atopic derma-
titis and pemphigus patients, for example, receive their 
IVIG infusion on an outpatient basis, limiting our obser-
vation of adverse reactions to immediate adverse effects; 
therefore, adverse effects occurring subsequently may 
have been missed.
This study indicates that, despite common prophy-
lactic measures, IVIG preparations are not all equally 
well tolerated in patients. However, the results suggest 
an influence of the infusion rate. Indeed, the present 
data suggest that the side-effects may be strongly as-
sociated with the infusion rate, which was not adapted 
to the concentration of the different products. This is 
supported by the observation that most of the adverse 
events resolved, or reduced, after lowering the infusion 
rate (cf. subsequent management, Table SI). In the case 
of mild adverse reactions in a given patient, one should 
first adapt the infusion rate to the body weight of the 
patient before, in a second step, considering substitu-
ting another IVIG preparation. Correct hydration of the 
patient should be ensured before therapy. In conclusion, 
this study shows that side-effects of IVIG are associa-
ted with the concentration of the product, and that the 
infusion rate has to be adapted. 
The authors declare no conflict of interest.
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Table III. Characteristics of intravenous immunoglobulin products cited including properties and excipients that may account for side-
effects (sugar and sodium content, osmolarity, pH and IgA content)
Redimune NF Liquid® Octagam® Endobulin®
Manufacturer or distributor ZLB Bioplasma Octapharma Baxter
Formulation Liquid Liquid Lyophilized
Reconstitution time (min) None (liquid solution) None (liquid solution) Several
Available concentration (%) 12 5 5
Maximum recommended infusion rate (ml/kg/h) 1 4.2 8
Sugar content None 100 mg/ml maltose 50 mg/ml ± 5 mg
Sodium content < 10 mmol/l 1.75 mg/ml 3 mg/ml ± 1 mg
Osmolarity 360 mOsm/kg 310–380 mOsm/kg 357 mOsm/kg
pH 5.3 5.1–6 7
IgA content < 100 µg/ml < 100 µg/ml < 50 µg/ml
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